“We have voice”- The Indian Drug Makers.

Global Drug makers of INDIA have a proposal for Indian Government and it’s been considered. MNC’s trying to make love with PMO (Prime Minister Office) and the villain flags hoisted by Domestic Industry and Public Health Activity. The proposal of global drug makers seeks certain changes in the countries IPR. PMO in retort asks Ministry of commerce, Health and Family welfare department of legal affairs to admit their opinion spotlighting ‘the changes in controversial matters of Legislative review of section 3(d)’ of Indian Patent Act and a clear definition of ‘efficacy’ criteria since requested by the Drug makers in the proposal.

Section 3(d) articulates “No grant of patent for incremental innovations unless it provide significant thereupatic advantages to existing molecules”. Indian Courts and Patent Office shuts off the claims specified by global drug makers via this provision. See details

Foreign Drug makers VS Local Firms:

Global MNC’s seek ‘Alignment in Applicable statutes’ in simple, ‘a fixed law of Government’. The foreign drug maker supporting provision could avert local companies launching generic versions of patented medicines. The version of global drug makers voices that ‘The regime doesn’t encourage innovation’.

MNC’s to PMO:

Rights granted under one statute should not be defeated under the other.The words stand for ‘The legislation in the country should be aligned’.

MNC’s again! ‘Patent Linkage’

The patent linkage in normal terminology suggests the linkage status of patent grant, for drugs while these MNC’s are in note. Domestic Industry and Public Health Activists oppose the same in opinion of this provision would front to increase in drug price in country by delaying the entry of low cost generic version of drugs, which is a very true fact for a country like India should underline the public in remainder. And the same has been completed by the Indian Courts dismissing the appeal by Bayer Corporation (Patent Linking proposal) says Drug Controller General of India (DCGI) should not give marketing approval to Cipla’s generic version of formers renal cancer drug ‘Nexavar’. Many controversies as such are arisen in the past and still the same continued in our country.